BACKGROUND: Previous studies of hereditary retinoblastoma survivors have reported elevated mortality, particularly for sarcomas, compared with the general population. However, cause-specific mortality patterns for long-term hereditary and nonhereditary retinoblastoma survivors are poorly understood. METHODS: Among 2053 retinoblastoma patients diagnosed during 1914-2006 at two major US treatment centers and followed to 2016, we estimated cumulative mortality, standardized mortality ratios (SMRs), and absolute excess risks (AERs) compared with the US general population. RESULTS: Most deaths occurred in 1129 hereditary retinoblastoma patients (n = 518 deaths, cumulative mortality 70 years after retinoblastoma = 75.8%, 95% CI = 69.0% to 82.6%; SMR = 8.5, 95% CI = 7.7 to 9.2). Of these, 267 were due to subsequent cancers (SMR = 27.4, 95% CI = 24.2 to 30.9; AER = 72.3 deaths/10 000 person-years), for which SMRs were highest 15-29 years after diagnosis (n = 69, SMR = 89.9, 95% CI = 70.0 to 113.8) but remained statistically significantly elevated at 60 and more years (n = 14, SMR = 6.7, 95% CI = 3.6 to 11.2), whereas AERs increased with time (AER<15years = 38.0; AER60+years = 327.5). Increased risk of death due to cancers of pancreas, large intestines, and kidney were noted for the first time. Overall risk of subsequent cancers was greater for those treated with radiotherapy and chemotherapy compared to radiotherapy alone, although patterns varied by organ site. For 924 patients with nonhereditary retinoblastoma, we noted a modestly increased risk of death for subsequent cancers (n = 27, SMR = 1.8, 95% CI = 1.2 to 2.6) possibly due to treatment or misclassification of hereditary status. Risks of noncancer causes of death were not elevated for hereditary or nonhereditary patients. CONCLUSION: Hereditary retinoblastoma survivors died mainly from an excess risk of subsequent cancers up to six decades later, highlighting the need to develop long-term clinical management guidelines for hereditary retinoblastoma survivors treated in the past. Published by Oxford University Press 2019.
BACKGROUND: Previous studies of hereditary retinoblastoma survivors have reported elevated mortality, particularly for sarcomas, compared with the general population. However, cause-specific mortality patterns for long-term hereditary and nonhereditary retinoblastoma survivors are poorly understood. METHODS: Among 2053 retinoblastomapatients diagnosed during 1914-2006 at two major US treatment centers and followed to 2016, we estimated cumulative mortality, standardized mortality ratios (SMRs), and absolute excess risks (AERs) compared with the US general population. RESULTS: Most deaths occurred in 1129 hereditary retinoblastomapatients (n = 518 deaths, cumulative mortality 70 years after retinoblastoma = 75.8%, 95% CI = 69.0% to 82.6%; SMR = 8.5, 95% CI = 7.7 to 9.2). Of these, 267 were due to subsequent cancers (SMR = 27.4, 95% CI = 24.2 to 30.9; AER = 72.3 deaths/10 000 person-years), for which SMRs were highest 15-29 years after diagnosis (n = 69, SMR = 89.9, 95% CI = 70.0 to 113.8) but remained statistically significantly elevated at 60 and more years (n = 14, SMR = 6.7, 95% CI = 3.6 to 11.2), whereas AERs increased with time (AER<15years = 38.0; AER60+years = 327.5). Increased risk of death due to cancers of pancreas, large intestines, and kidney were noted for the first time. Overall risk of subsequent cancers was greater for those treated with radiotherapy and chemotherapy compared to radiotherapy alone, although patterns varied by organ site. For 924 patients with nonhereditary retinoblastoma, we noted a modestly increased risk of death for subsequent cancers (n = 27, SMR = 1.8, 95% CI = 1.2 to 2.6) possibly due to treatment or misclassification of hereditary status. Risks of noncancer causes of death were not elevated for hereditary or nonhereditary patients. CONCLUSION:Hereditary retinoblastoma survivors died mainly from an excess risk of subsequent cancers up to six decades later, highlighting the need to develop long-term clinical management guidelines for hereditary retinoblastoma survivors treated in the past. Published by Oxford University Press 2019.
Authors: Ruth A Kleinerman; Margaret A Tucker; David H Abramson; Johanna M Seddon; Robert E Tarone; Joseph F Fraumeni Journal: J Natl Cancer Inst Date: 2007-01-03 Impact factor: 13.506
Authors: Meredith C Foster; Ruth A Kleinerman; David H Abramson; Johanna M Seddon; Robert E Tarone; Margaret A Tucker Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-08 Impact factor: 4.254
Authors: A Acquaviva; L Ciccolallo; R Rondelli; A Balistreri; R Ancarola; R Cozza; D Hadjistilianou; S De Francesco; P Toti; G Pastore; R Haupt; M Carli; N Santoro; A Di Cataldo; A Fiorillo; P Indolfi; P Nucci; A Sandri; F Porta; A B Porcaro; P Tamaro; G Morgese Journal: Oncogene Date: 2006-08-28 Impact factor: 9.867
Authors: Ruth A Kleinerman; Margaret A Tucker; Robert E Tarone; David H Abramson; Johanna M Seddon; Marilyn Stovall; Frederick P Li; Joseph F Fraumeni Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Chu-Ling Yu; Margaret A Tucker; David H Abramson; Kyoji Furukawa; Johanna M Seddon; Marilyn Stovall; Joseph F Fraumeni; Ruth A Kleinerman Journal: J Natl Cancer Inst Date: 2009-04-07 Impact factor: 13.506
Authors: Tamara Marees; Annette C Moll; Saskia M Imhof; Michiel R de Boer; Peter J Ringens; Flora E van Leeuwen Journal: J Natl Cancer Inst Date: 2008-12-09 Impact factor: 13.506
Authors: Joseph P Neglia; Leslie L Robison; Marilyn Stovall; Yan Liu; Roger J Packer; Sue Hammond; Yutaka Yasui; Catherine E Kasper; Ann C Mertens; Sarah S Donaldson; Anna T Meadows; Peter D Inskip Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 11.816
Authors: Nagma Dalvi; Ruth A Kleinerman; Sidnei Epelman; David H Abramson; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2020-10-16 Impact factor: 3.167
Authors: Milo van Hoefen Wijsard; Sara J Schonfeld; Flora E van Leeuwen; Annette C Moll; Armida W Fabius; David H Abramson; Johanna M Seddon; Jasmine H Francis; Margaret A Tucker; Ruth A Kleinerman; Lindsay M Morton Journal: Cancers (Basel) Date: 2021-04-08 Impact factor: 6.639
Authors: Ruth A Kleinerman; Sara J Schonfeld; David H Abramson; Jasmine H Francis; Johanna M Seddon; Lindsay M Morton; Margaret A Tucker Journal: J Invest Dermatol Date: 2021-06-18 Impact factor: 7.590
Authors: Ruth A Kleinerman; Sara J Schonfeld; Byron S Sigel; Jeannette R Wong-Siegel; Ethel S Gilbert; David H Abramson; Johanna M Seddon; Margaret A Tucker; Lindsay M Morton Journal: J Clin Oncol Date: 2019-10-17 Impact factor: 44.544
Authors: Pernille A Gregersen; Maja H Olsen; Steen F Urbak; Mikkel Funding; Susanne O Dalton; Jens Overgaard; Jan Alsner Journal: JAMA Netw Open Date: 2020-10-01
Authors: Sara J Schonfeld; Ruth A Kleinerman; David H Abramson; Johanna M Seddon; Margaret A Tucker; Lindsay M Morton Journal: Br J Cancer Date: 2021-01-21 Impact factor: 7.640